Related Experiment Videos
NSAIDs and the gastrointestinal tract: an update on recent progress
The Journal of the American Osteopathic Association
|March 25, 2000
Summary
New advancements in cyclooxygenase-2 (COX-2) technology may improve the safety of nonsteroidal anti-inflammatory drug (NSAID) therapy. This review examines COX-1 and COX-2 inhibition mechanisms and their impact on gastrointestinal and liver health.
Area of Science:
- Pharmacology
- Gastroenterology
- Drug Safety
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- NSAID use is associated with gastrointestinal (GI) complications, including ulcer disease.
- Cyclooxygenase enzymes, COX-1 and COX-2, are key targets for NSAID action.
Purpose of the Study:
- To outline the mechanisms of specific cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibition.
- To evaluate the safety profile of NSAID therapy, particularly concerning newer COX-2 technologies.
- To review gastrointestinal and liver-related issues associated with NSAID use.
Main Methods:
- Review of existing literature on COX-1 and COX-2 inhibition mechanisms.
- Analysis of safety data for NSAIDs, focusing on advancements in COX-2 technology.
- Examination of clinical evidence regarding gastrointestinal and liver diseases linked to NSAIDs.
Main Results:
- Specific inhibition of COX-1 and COX-2 pathways influences NSAID safety profiles.
- Emerging COX-2 technologies show potential for an improved safety margin in NSAID therapy.
- Gastrointestinal complications like ulcer disease and potential liver issues remain critical considerations.
Conclusions:
- Understanding COX-1 and COX-2 inhibition is crucial for NSAID safety.
- Advancements in COX-2 selective agents may mitigate risks associated with traditional NSAIDs.
- Continued monitoring for gastrointestinal and liver adverse events is essential for patients on NSAID therapy.